| Name | Title | Contact Details |
|---|
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.
Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
Arnold A Welu Dental Laboratory, Inc is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.